RE: Fool's GoldRE: Fools Gold - this isn't the US and we tend to not get US type
valuations.
Got my AGM materials - The new company likes to spend money
on Price Waterhouse Reports - Annual Reports, meetings at the
Royal York. What's with all the spending at such an ealry stage?
---------------------------------------
PricewaterhouseCoopers Securities Inc. has had a client
relationship with Prescient NeuroPharma Inc. in the last 12
months.
VALUATION Milestones
Prescient has set several major milestones for the next
fiscal year.
- Prescient plans to sell the Phase I cancer asset and is
currently in discussions with interested parties. The deal
structure would potentially involve an initial payment and
contingent payments upon completion of Phase II and III.
Prescient would receive a share of any royalties achieved, which
may be capped at a specified amount.
- Prescient plans to name the lead molecule and disease in the
small molecule mGluR program in the fall of 2001, and to
commence partnering discussions at that point in time.
Prescient's goal is to conclude those discussions by Q-2,
2002 and to proceed to an IND/Phase I by Q-4, 2002 or Q1,
2003.
- Prescient plans to complete additional financings which
total
$20 million to $30 million to fund development plans for 2002
through 2005. This global financing requirement will allow for
optimization of shareholder value.
----------------------------------
????